Last
Update:
July 30, 2015
Perinatal Journal Data are integrated with Perinatal Conference Data in
the Perinatal Data Page.
Pediatric Journal Data are integrated with Pediatric Conference Data in
the Pediatric Data Page
 Documents identified with this icon
are in Portable Document Format (PDF) and require the
Adobe
Acrobat Reader.
XX
International AIDS Conference
|
M. Rheeders, R.
Reay, M. Viljoen, C. Dandara
Abstract
The drug interaction between rifampicin and
efavirenz is time-dependent: systematic review of 12
pharmacokinetic studies
M. Boffito, A. Hill, S. Khoo, et al
Abstract
Use of efavirenz is not associated to an increased
risk of neurocognitive impairment in HIV-infected
patients
C. Pinnetti, P. Balestra, R. Libertone, et al
Abstract
Appraisal of efavirenz use in patients with
nevirapine induced Steven Johnson syndrome
T.C. Manzini, M.Y.S. Moosa
Abstract
Improved virological outcomes amongst adults
starting efavirenz for first-line antiretroviral
treatment in a multicentre cohort study in South
Africa
G.L. Fatti, B. Egbujie, D. Solomon, et al
Abstract
Lopinavir/r vs efavirenz/FTC/TDF for HIV maintenance
therapy: results of the ANRS 140 DREAM trial
J.-L. Meynard, L. Moino, A. Perrier, et al
Abstract
-
POSTER
Prevalence of rilpivirine and etravirine resistance mutations in HIV-1 non-B
subtypes infected patients failing to non-nucleoside transcriptase
inhibitor-based therapies in Mali
A.I. Maiga, F. Dao, A. Balde, et al
Poster
Abstract
-
Plasma efavirenz
concentrations in HIV-infected children in Thailand: comparison between FDA and
WHO 2010 dosing guidelines
N. Homkham S. Urien, T.R. Cressey, et al
Abstract
-
A daily dose of 400mg
efavirenz (EFV) is non-inferior to the standard 600mg dose: week 48 data from
the ENCORE1 study, a randomised, double-blind, placebo controlled,
non-inferiority trial
R. Puls, Encore1 Study Group
Absract
-
Efavirenz Pharmacokinetics Are Independently Associated with
Virologic Failure in Diverse-Resource Limited Settings
Adriana Andrade, G Baheti, L
Smeaton, et al
Abstract
-
Differential Subcutaneous Adipose Tissue Gene Expression Pattern
with 1st-line Treatment Containing either Efavirenz or Lopinavir/ritonavir
Lander Egana-Gorrono, E Martinez,
M Lonca, et al
Abstract
-
Differential Induction of Efavirenz Metabolism by Rifampin
without and with Isoniazid in Healthy Volunteers with CYP2B6 516GG and TT
Genotypes
L awrence
Lee, GH Soon, N Chew. et al
Abstract
-
Relationship between CYP2B6 Haplotype and Virologic Response to
Efavirenz-containing Regimens in Port-au-Prince, Haiti
David Haas, P Severe, M-A Juste,
et al
Abstract
-
Week-24 Primary Analysis of Cenicriviroc vs Efavirenz, in
Combination with Emtricitabine/Tenofovir, in Treatment-naïve HIV-1+
Adults with CCR5-tropic Virus
Joseph Gathe, J Cade, E DeJesus,
et al
Abstract
-
Identification of Isoniazid as a Potent Inhibitor of
CYP2A6-mediated Efavirenz 7-hydroxylation in CYP2B6*6 Genotyped Human Liver
Microsomes
M Court, F Almutairi, D
Greenblatt, et al
Abstract
XIX
International AIDS Conference
|
-
POSTER
Lopinavir
and efavirenz concentrations in paired hair samples as a marker of cumulative
exposure among postpartum women and breastfeeding infants in Tororo, Uganda
J. Mwesigwa, D. Cohan, A. Plenty, et al
Poster
Abstract
-
POSTER
A single nucleotide polymorphism in CYP2B6 leads to >3-fold increases in
efavirenz concentrations in intensive pharmacokinetic curves and hair samples
M. Gandhi, R. Greenblatt, P. Bacchetti, et al
Poster
Abstract
-
POSTER
Efavirenz and nevirapine significantly affect artemether-lumefantrine
pharmacokinetic exposure in HIV-positive Ugandan adults
P. Byakika-Kibwika,, M. Lamorde, H. Mayanja-Kizza. et al
Poster
Abstract
-
Initial tolerability
of rilpivirine (RPV, TMC278) and efavirenz (EFV) in the phase III ECHO and
THRIVE trials:
profile of grade 1 events
B. Rashbaum, P.-M. Girard, A. Rachlis. et al
Abstract
-
Substitutions to initial antiretroviral therapy in children in South Africa: the
international epidemiologic databases to evaluate AIDS, Southern Africa
(IeDEA-SA) Collaboration
L. Kampiire, D. Garone, J. Giddy, et al
Abstract
-
Relationship between
weight, efavirenz (EFV) concentrations and virologic suppression in HIV+
patients
on rifampin (RIF)-based TB treatment in the ACTG 5221 STRIDE study
A.F. Luetkemeyer, S.L. Rosenkranz, D. Lu, et al
Abstract
-
Efavirenz (EFV) concentrations in pregnant women taking EFV-based antiretroviral
therapy (ART) with and without
rifampin-containing tuberculosis (TB) treatment: the TSHEPISO Study Team
H. McIlleron, N. Martinson, P. Denti, et al
Abstract
-
Effectiveness of
EFV-based ART regimens in young children requiring TB/HIV co-treatment: a
possible treatment option
for resource-limited
settings
J.H. van Dijk, C.G. Sutcliffe, F. Hamangaba.
et al
Abstract
-
Examining the effect
of rfampicin and CYP2B6 genotype on efavirenz auto-induction and exposure in
Tanzanian
HIV patients with and
without tuberculosis: a prospective comparative study
E. Ngaimisi, S. Mugusi, O.M.S. Minzi, et al
Abstract
-
Population
pharmacokinetics of efavirenz in HIV-1-positive Thai children
N. Homkham. Urien, T.R. Cressey, et al
Abstract
-
Compulsory licence and
access to medicines: economic savings of efavirenz in Brazil
F. Viegas Neves da Silva, R. Hallal, A.
Guimarăes
Abstract
-
The effect of
depression risk in HIV patients on antiretroviral therapy (ART) choice and the
risk of
subsequent depression
diagnosis after exposure
B. Wong, W. Zachry, III, K.-T. Tsai, et al
Abstract
-
Use of a liquid
chromatography/mass spectrometry (LC/MS) in vitro assay to quantify nevirapine
(NVP), efavirenz (EFV) and lamivudine (3-TC) on dried blood-spot (DBS) samples:
a strategy to evaluate adherence to prevention-of-mother-to-child-transmission
E.H. Kouman, A. Martin, M.R. Adler, et al
|
Efavirenz
Main Page
Main
New/Newsworthy
